Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2020

01-09-2020 | Breast Cancer | Clinical trial

External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery

Authors: Ji-Jung Jung, Eunyoung Kang, Eun-Kyu Kim, Sun Mi Kim, Mijung Jang, Bo La Yun, So Yeon Park, Hee-Chul Shin

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Login to get access

Abstract

Purpose

A positive resection margin after breast conserving surgery (BCS) is the most important risk factor for tumor recurrence. In 2012, Seoul National University Hospital (SNUH) breast surgery team developed a nomogram for predicting positive resection margins before BCS to provide individual surgical plans that could reduce local recurrence without increasing re-excision rates. The purpose of this study was to validate this nomogram using an external cohort and to test if addition of surgeon-related factor could improve its use as a predictive model.

Methods

A total of 419 patients with breast cancer who underwent BCS from January to December 2018 were retrospectively reviewed. Using the SNUH BCS nomogram, risk score for positive resection margins was calculated for 343 patients. The predictive accuracy of the nomogram was assessed, and multivariable logistic regression analyses were performed to evaluate the nomogram’s predictive variables.

Results

The positive resection margin rate of the current external validation cohort was 13.5% (46 out of 343), compared to 14.6% (151 out of 1034) of the original study. The discrimination power of the SNUH BCS nomogram as measure by area under the receiver operating characteristics curve (AUC) was 0.656 [95% confidence interval (CI) 0.576–0.735]. This result is lower than expected value of 0.823 [95% CI 0.785–0.862], the AUC of the original study. Multivariable logistic regression analysis showed that, among the five nomogram variables, presence of tumor size discrepancy greater than 0.5 cm between MRI and ultrasonography (OR 2.445, p = 0.019) and presence of ductal carcinoma in situ on needle biopsy (OR 2.066, p = 0.048) were significantly associated with positive resection margins. Finally, the nomogram score was re-calculated by adding each surgeon’s resection margin positive rate as odds ratio and the AUC was increased to 0.733.

Conclusions

Validation of the SNUH BCS nomogram was not successful in the current study as much as its original publication. However, we could improve its predictive power by including surgeon-related factor. Before applying a published nomogram as a preoperative predictive model, we suggest each institution to validate the model and adjust it with surgeon-related factor. Addition of new factors to currently available nomograms holds promise for improving its applicability for breast cancer patients at the actual clinical level.
Literature
8.
go back to reference Poirier E, Sideris L, Dube P et al (2008) Analysis of clinical applicability of the breast cancer nomogram for positive sentinel lymph node: the Canadian experience. Ann Surg Oncol 15:2562–2567CrossRef Poirier E, Sideris L, Dube P et al (2008) Analysis of clinical applicability of the breast cancer nomogram for positive sentinel lymph node: the Canadian experience. Ann Surg Oncol 15:2562–2567CrossRef
10.
go back to reference Lambert LA, Ayers GD, Hwang RF et al (2006) Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 13:310–320CrossRef Lambert LA, Ayers GD, Hwang RF et al (2006) Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 13:310–320CrossRef
17.
go back to reference Fischer JE, Bachmann LM, Jaeschke R (2003) A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 29:1043–1051CrossRef Fischer JE, Bachmann LM, Jaeschke R (2003) A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 29:1043–1051CrossRef
18.
go back to reference Peintinger F (2011) Clinical use of nomograms for breast cancer. J Surg Oncol 103:745CrossRef Peintinger F (2011) Clinical use of nomograms for breast cancer. J Surg Oncol 103:745CrossRef
22.
go back to reference Rahman GA (2011) Editorial: breast conserving therapy: a surgical technique where little can mean more. J Surg Tech Case Rep 3:1–4CrossRef Rahman GA (2011) Editorial: breast conserving therapy: a surgical technique where little can mean more. J Surg Tech Case Rep 3:1–4CrossRef
25.
go back to reference Taghian A, Mohiuddin M, Jagsi R et al (2005) Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey. Ann Surg 241:629–639CrossRef Taghian A, Mohiuddin M, Jagsi R et al (2005) Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey. Ann Surg 241:629–639CrossRef
33.
go back to reference Brouwer de Koning SG, Vrancken Peeters MJTFD, Jóźwiak K et al (2018) Tumor resection margin definitions in breast-conserving surgery: systematic review and meta-analysis of the current literature. Clin Breast Cancer 18:e595–e600CrossRef Brouwer de Koning SG, Vrancken Peeters MJTFD, Jóźwiak K et al (2018) Tumor resection margin definitions in breast-conserving surgery: systematic review and meta-analysis of the current literature. Clin Breast Cancer 18:e595–e600CrossRef
Metadata
Title
External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery
Authors
Ji-Jung Jung
Eunyoung Kang
Eun-Kyu Kim
Sun Mi Kim
Mijung Jang
Bo La Yun
So Yeon Park
Hee-Chul Shin
Publication date
01-09-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05779-z

Other articles of this Issue 2/2020

Breast Cancer Research and Treatment 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine